Nymox Pharmaceutical Corporation (NYMXF)

Nymox Pharmaceutical Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	-	-	-	-	0.01	0.12
Revenue Growth (YoY)	-	-	-	-	-95.69%	-61.20%
Cost of Revenue	-	-	-	-	0	0.06
Gross Profit	-	-	-	-	0	0.06
Selling, General & Admin	3.67	4.36	2.88	5.85	3.6	6.01
Research & Development	4.68	3.99	3.77	6.66	8.12	7.38
Operating Expenses	8.35	8.35	6.65	12.5	11.72	13.38
Operating Income	-8.35	-8.35	-6.65	-12.5	-11.72	-13.33
Interest Expense	-0.17	-0.06	-0.04	-0.04	-0.04	-0.04
Interest & Investment Income	0.01	0.01	0	0.01	0.03	0.21
Currency Exchange Gain (Loss)	0	0	0.01	-0	-0	-0.01
Other Non Operating Income (Expenses)	-	-	0.11	-	-	-
EBT Excluding Unusual Items	-8.51	-8.4	-6.58	-12.54	-11.74	-13.16
Other Unusual Items	-0.44	-0.44	-	-	-	-
Pretax Income	-8.95	-8.84	-6.58	-12.54	-11.74	-13.16
Net Income	-8.95	-8.84	-6.58	-12.54	-11.74	-13.16
Net Income to Common	-8.95	-8.84	-6.58	-12.54	-11.74	-13.16
Shares Outstanding (Basic)	93	92	89	82	74	69
Shares Outstanding (Diluted)	93	92	89	82	74	69
Shares Change (YoY)	2.87%	2.58%	9.04%	11.04%	7.23%	13.86%
EPS (Basic)	-0.10	-0.10	-0.07	-0.15	-0.16	-0.19
EPS (Diluted)	-0.10	-0.10	-0.07	-0.15	-0.16	-0.19
Free Cash Flow	-2.78	-4.06	-5.21	-9.83	-10.05	-7.43
Free Cash Flow Per Share	-0.03	-0.04	-0.06	-0.12	-0.14	-0.11
Gross Margin	-	-	-	-	20.00%	50.00%
Operating Margin	-	-	-	-	-234400.00%	-11487.07%
Profit Margin	-	-	-	-	-234760.00%	-11346.55%
Free Cash Flow Margin	-	-	-	-	-201000.00%	-6405.17%
EBITDA	-8.34	-8.34	-6.64	-12.49	-11.71	-13.32
D&A For EBITDA	0	0.01	0.01	0.01	0.01	0.01
EBIT	-8.35	-8.35	-6.65	-12.5	-11.72	-13.33
Revenue as Reported	-	-	-	-	0.01	0.12

Updated Jan 2, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.